453 related articles for article (PubMed ID: 22914208)
21. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy.
Barentsen R; van de Weijer PH; Schram JH
Eur J Obstet Gynecol Reprod Biol; 1997 Jan; 71(1):73-80. PubMed ID: 9031963
[TBL] [Abstract][Full Text] [Related]
22. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
Portman D; Palacios S; Nappi RE; Mueck AO
Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
[TBL] [Abstract][Full Text] [Related]
23. Effects of ultralow topical estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse.
Caruso S; Cianci S; Vitale SG; Matarazzo MG; Amore FF; Cianci A
Menopause; 2017 Aug; 24(8):900-907. PubMed ID: 28350758
[TBL] [Abstract][Full Text] [Related]
24. Role of high molecular weight hyaluronic acid in postmenopausal vaginal discomfort.
Grimaldi EF; Restaino S; Inglese S; Foltran L; Sorz A; Di Lorenzo G; Guaschino S
Minerva Ginecol; 2012 Aug; 64(4):321-9. PubMed ID: 22728576
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
De Seta F; Caruso S; Di Lorenzo G; Romano F; Mirandola M; Nappi RE
Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
[TBL] [Abstract][Full Text] [Related]
26. Comparative uterine effects on ovariectomized rats after repeated treatment with different vaginal estrogen formulations.
López-Belmonte J; Nieto C; Estevez J; Delgado JL; del Prado JM
Maturitas; 2012 Aug; 72(4):353-8. PubMed ID: 22683083
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis.
Chollet JA; Carter G; Meyn LA; Mermelstein F; Balk JL
Menopause; 2009; 16(5):978-83. PubMed ID: 19390463
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women.
Dessole S; Rubattu G; Ambrosini G; Gallo O; Capobianco G; Cherchi PL; Marci R; Cosmi E
Menopause; 2004; 11(1):49-56. PubMed ID: 14716182
[TBL] [Abstract][Full Text] [Related]
29. Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy.
Jaisamrarn U; Triratanachat S; Chaikittisilpa S; Grob P; Prasauskas V; Taechakraichana N
Climacteric; 2013 Jun; 16(3):347-55. PubMed ID: 23347400
[TBL] [Abstract][Full Text] [Related]
30. The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial.
Zohrabi I; Abedi P; Ansari S; Maraghi E; Shakiba Maram N; Houshmand G
BMC Womens Health; 2020 May; 20(1):108. PubMed ID: 32429977
[TBL] [Abstract][Full Text] [Related]
31. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
Kroll R; Archer DF; Lin Y; Sniukiene V; Liu JH
Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
[TBL] [Abstract][Full Text] [Related]
32. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy.
Parsons A; Merritt D; Rosen A; Heath H; Siddhanti S; Plouffe L;
Obstet Gynecol; 2003 Feb; 101(2):346-52. PubMed ID: 12576260
[TBL] [Abstract][Full Text] [Related]
33. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy.
Dugal R; Hesla K; Sørdal T; Aase KH; Lilleeidet O; Wickstrøm E
Acta Obstet Gynecol Scand; 2000 Apr; 79(4):293-7. PubMed ID: 10746845
[TBL] [Abstract][Full Text] [Related]
34. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women.
Cruz VL; Steiner ML; Pompei LM; Strufaldi R; Fonseca FLA; Santiago LHS; Wajsfeld T; Fernandes CE
Menopause; 2018 Jan; 25(1):21-28. PubMed ID: 28763401
[TBL] [Abstract][Full Text] [Related]
35. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):907-22. PubMed ID: 19436225
[TBL] [Abstract][Full Text] [Related]
36. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study.
Biglia N; Peano E; Sgandurra P; Moggio G; Panuccio E; Migliardi M; Ravarino N; Ponzone R; Sismondi P
Gynecol Endocrinol; 2010 Jun; 26(6):404-12. PubMed ID: 20196634
[TBL] [Abstract][Full Text] [Related]
37. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
Bachmann G; Bobula J; Mirkin S
Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
[TBL] [Abstract][Full Text] [Related]
38. Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study.
Jonasson AF; Edwall L; Uvnäs-Moberg K
Menopause Int; 2011 Dec; 17(4):120-5. PubMed ID: 22120944
[TBL] [Abstract][Full Text] [Related]
39. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial.
Simon JA; Bouchard C; Waldbaum A; Utian W; Zborowski J; Snabes MC
Obstet Gynecol; 2007 Mar; 109(3):588-96. PubMed ID: 17329509
[TBL] [Abstract][Full Text] [Related]
40. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.
Hedrick RE; Ackerman RT; Koltun WD; Halvorsen MB; Lambrecht LJ
Menopause; 2009; 16(1):132-40. PubMed ID: 18971794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
